Myricx Bio develops novel payloads for antibody-drug conjugates (ADCs) that inhibit N-myristoyltransferases (NMT) to target cancer cells. Their proprietary ADCs demonstrate significant preclinical efficacy and safety against various solid tumor-associated antigens, addressing the need for effective cancer treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers remain difficult to treat effectively due to limitations in current therapeutic approaches. Traditional antibody-drug conjugates (ADCs) may not always provide sufficient efficacy or may exhibit toxic side effects, highlighting the need for novel cancer-targeting strategies.
Solution
Myricx Bio is developing a new class of antibody-drug conjugates (ADCs) that target cancer cells by inhibiting N-myristoyltransferases (NMT). These novel payloads are designed to disrupt the NMT enzymes, which play a crucial role in cancer cell growth and survival. Myricx's proprietary ADCs have demonstrated significant preclinical efficacy and safety across multiple solid tumor-associated antigens and cancer cell types. This approach aims to provide a more targeted and effective cancer treatment option with improved outcomes.
Target Audience
The primary target audience includes oncology researchers and pharmaceutical companies focused on developing innovative cancer therapies.
Features
- Novel ADC payloads based on NMT inhibition
- Demonstrated preclinical efficacy against various solid tumor-associated antigens
- Improved safety profile in preclinical studies
- Proprietary pipeline of new generation ADCs